Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)
FDA Inspection
•SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)•June 27, 2017

SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals) – FDA Inspection, Jun 27, 2017

Record Details

This FDA Inspection record concerns SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals), with an inspection on June 27, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.

Company
SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)
Inspection Date
June 27, 2017
Product Type
Biologics
Office
Center for Biologics Evaluation and Research
People
  • Gene D. Arcy
  • Mihaly S. Ligmond (FDA Associated Person)
  • Steven A. Rubin (Company Rep)
View Company Profile

ID · e4847276-f3f0-4073-a7d2-e60f6d62c3c5

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
1019795
FDA center
Biologics
Project area
Vaccines and Allergenic Products
Outcome
Form 483 issued

Other FDA inspections of SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)

6
DateClassificationOfficeProject area
March 15, 2024VAICenter for Biologics Evaluation and ResearchVaccines and Allergenic Products
September 20, 2022VAICenter for Biologics Evaluation and ResearchVaccines and Allergenic Products
July 5, 2019NAICenter for Biologics Evaluation and ResearchVaccines and Allergenic Products
June 22, 2011VAICenter for Biologics Evaluation and ResearchVaccines and Allergenic Products
May 24, 2010VAICenter for Biologics Evaluation and ResearchVaccines and Allergenic Products
View all 6 other inspections on the company page
Other documents for SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)
  • FDA Inspection 1233707 - 2024-03-15
  • FDA Inspection 1181891 - 2022-09-20
  • FDA Inspection 1101506 - 2019-07-05
  • FDA Inspection 736162 - 2011-06-22
  • FDA Inspection 668686 - 2010-05-24

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore SmithKline Beecham Pharma GmbH & co. KG (dba GlaxoSmithKline Biologicals)
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.